Sana Biotechnology Inc SANA.OQ SANA.O is expected to show no change in quarterly revenue when it reports results on May 6 (estimated) for the period ending March 31 2025
LSEG's mean analyst estimate for Sana Biotechnology Inc is for a loss of 23 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Sana Biotechnology Inc is $9.00, above its last closing price of $1.90.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.23
-0.21
Beat
7.2
Sep. 30 2024
-0.25
-0.25
-0.25
Met
-0.1
Jun. 30 2024
-0.28
-0.28
-0.21
Beat
26.3
Mar. 31 2024
-0.33
-0.32
-0.49
Missed
-54.1
Dec. 31 2023
-0.38
-0.38
-0.41
Missed
-7.9
Sep. 30 2023
-0.43
-0.45
0.02
Beat
104.5
Jun. 30 2023
-0.42
-0.43
-0.59
Missed
-38.3
Mar. 31 2023
-0.42
-0.45
-0.43
Beat
3.7
This summary was machine generated May 2 at 11:18 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)